Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811589 | 0.91 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3ERCC5FEN1 | |
| SCHEMBL4552092 | 0.84 | ERCC5 (0.46) | SLC6A2SLC6A4SLC6A3ERCC5FEN1 | |
| SCHEMBL4811598 | 0.83 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3ERCC5FEN1 | |
| SCHEMBL2292145 | 0.80 | ALDH1A1 (0.52) | ERCC5FEN1TSHRHPGDPOLB | |
| SCHEMBL27960653 | 0.80 | CES2 (0.50) | ERCC5FEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL4326257 | 0.80 | CES2 (0.50) | ERCC5FEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL10446352 | 0.79 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3ERCC5FEN1 | |
| SCHEMBL12984351 | 0.79 | TSHR (0.41) | SLC6A2SLC6A4SLC6A3ERCC5FEN1 | |
| SCHEMBL24465233 | 0.79 | LMNA (0.57) | SLC6A2SLC6A4SLC6A3ERCC5FEN1 | |
| SCHEMBL8385259 | 0.79 | NR4A1 (0.56) | TSHRMAPK1HPGDKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080161282-A1 | Cytotoxic agents and methods of use | MIIKANA THERAPEUTICS, INC. | 2008-07-03 | — | — | US | disclosed |
| US-7371875-B2 | Cytotoxic agents and methods of use | MIIKANA THERAPEUTICS, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
| US-20050203162-A1 | Cytotoxic agents and methods of use | MIIKANA THERAPEUTICS CORPORATION | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203162-A1 | Cytotoxic agents and methods of use | XIAP, RIOX2, PSMA6 | SLC6A2 4587/4885SLC6A4 4555/4885SLC6A3 4644/4885 |
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | SLC6A2 2502/4885SLC6A4 620/4885SLC6A3 689/4885 |
| US-20080161282-A1 | Cytotoxic agents and methods of use | XIAP, RIOX2, PSMA6 | SLC6A2 4587/4885SLC6A4 4555/4885SLC6A3 4644/4885 |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | SLC6A2 2680/4885SLC6A4 2534/4885SLC6A3 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.